This document reviews the role of microRNAs (miRNAs) in cancer. It discusses how miRNAs are involved in regulating gene expression and cellular processes. Aberrant miRNA expression has been found in many cancer types and can influence cancer-related signaling pathways. The document summarizes the mechanisms that can lead to abnormal miRNA expression levels in cancer, including genetic alterations, epigenetic changes, and defects in the miRNA biogenesis pathway. It also discusses how miRNA profiling can be used for cancer diagnosis and how circulating miRNA levels in body fluids are being investigated as potential non-invasive diagnostic biomarkers.
The Role of MicroRNAs in the Progression, Prognostication, and Treatment of B...CrimsonpublishersCancer
1) The document discusses the role of microRNAs (miRNAs) in breast cancer progression, prognosis, and treatment. miRNAs are small non-coding RNA molecules that regulate gene expression and have been found to be dysregulated in many cancers.
2) The deregulation of specific miRNAs in breast cancer can act to promote or suppress tumor growth by affecting cancer hallmarks like cell proliferation, invasion, and metastasis. miRNAs show potential as biomarkers for breast cancer screening, prognosis, and response to treatment.
3) Recent research has shown that certain miRNAs are abnormally expressed in breast cancer tissues compared to normal tissues and may influence breast cancer initiation and development. Some miRNAs like miR-155 are upregulated in breast cancer and act as
An expression meta-analysis of predicted microRNA targets identifies a diagno...Yu Liang
This study identifies a 17-gene expression signature that can accurately classify lung adenocarcinoma and squamous cell carcinoma, the two major histological subtypes of lung cancer. The signature was developed by predicting microRNA target genes, filtering them based on gene ontology terms and ability to classify cancers, and analyzing gene expression data from multiple datasets. When validated in independent datasets, the signature correctly classified 87% of adenocarcinoma and 82% of squamous cell carcinoma samples on average. Expression of the signature also showed potential for early lung cancer detection in bronchial epithelial cells from smokers.
This document describes a study investigating the role of the protein Morgana in breast cancer metastasis. The study found that knocking down Morgana impaired migration, invasion, and metastasis of breast cancer cells in vitro and in vivo. Mechanistically, Morgana was found to increase the transcriptional activity of NF-κB, leading to increased expression of metastasis-promoting genes like MMP-9. Overexpressing Morgana had the opposite effect of increasing NF-κB target gene expression. Therefore, Morgana appears to promote breast cancer metastasis by activating the NF-κB pathway and increasing expression of pro-metastatic genes.
This document summarizes key signaling pathways in muscle-invasive bladder carcinoma. It discusses molecular markers that indicate basal or luminal subtypes of bladder cancer, which differ in response to treatment. Basal cancers often overexpress EGFR and respond to chemotherapy, while luminal cancers involve alterations in genes like FGFR3, ERBB2/3 and are generally less aggressive. The document also reviews markers for cancer stem cells, receptor tyrosine kinase signaling pathways, cytoskeleton proteins, the PI3K-Akt-mTOR pathway, and VEGF/VEGFR pathways that are clinically significant for modeling and optimizing treatment of muscle-invasive bladder cancer.
miRNA Breast Cancer Prognosis -- Ingenuity SystemsNatalie Ng
1) The document describes research to develop microRNA prognostic signatures that can predict breast cancer metastasis and determine which patients would benefit from chemotherapy.
2) Through computational modeling of miRNA and mRNA expression data, the researcher identified 5-miRNA signatures for ER-positive and ER-negative breast cancer.
3) In vitro experiments on breast cancer cell lines validated that the expressions of miRNAs in the signatures correlated with metastatic characteristics like migration, invasion and proliferation as predicted by the computational models.
11.06.13 - 2013 NIH Research Festival PosterFarhoud Faraji
The study uses systems genetics to identify a network of co-expressed genes centered on Cnot2 that predicts breast cancer metastasis. Cnot2 overexpression regulates the expression of network genes and modulates metastatic potential in vivo. Small RNA sequencing revealed miR-3470b as an upstream regulator of the Cnot2 network by downregulating its hub genes. miR-3470b promotes a pro-metastatic transcriptional profile and increases metastasis in vivo, demonstrating it plays a key role in regulating the metastatic process.
Characterization of microRNA expression profiles in normal human tissuesYu Liang
This document describes a study that characterized the expression profiles of microRNAs (miRNAs) in 40 normal human tissues. The researchers used quantitative real-time PCR to measure the expression levels of 345 miRNAs. They found that tissues from similar anatomical locations or with related physiological functions tended to cluster together based on their miRNA expression profiles. Many miRNAs showed exclusive or preferential expression in certain tissue types. The genomic locations of miRNAs also correlated with their expression patterns, as miRNAs located near each other on chromosomes often showed coordinated expression. The study provided a global view of miRNA tissue distribution and their potential roles in regulating normal tissue physiology.
- Certain miRNAs, such as miR-21 and miR-34a, show potential as biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) as their expression levels correlate with cancer progression and patient survival.
- Inhibiting overexpressed miRNAs in PDAC, such as miR-21, miR-221 and miR-222, using antagomirs delivered via lipoplex nanoparticles reduced tumor cell proliferation, invasion and restored chemosensitivity in cell line studies.
- Epithelial-mesenchymal transition (EMT), which is regulated by transcription factors and miRNAs and promotes metastasis, plays an important role in PDAC development. Controlling pathways involved in EMT
The Role of MicroRNAs in the Progression, Prognostication, and Treatment of B...CrimsonpublishersCancer
1) The document discusses the role of microRNAs (miRNAs) in breast cancer progression, prognosis, and treatment. miRNAs are small non-coding RNA molecules that regulate gene expression and have been found to be dysregulated in many cancers.
2) The deregulation of specific miRNAs in breast cancer can act to promote or suppress tumor growth by affecting cancer hallmarks like cell proliferation, invasion, and metastasis. miRNAs show potential as biomarkers for breast cancer screening, prognosis, and response to treatment.
3) Recent research has shown that certain miRNAs are abnormally expressed in breast cancer tissues compared to normal tissues and may influence breast cancer initiation and development. Some miRNAs like miR-155 are upregulated in breast cancer and act as
An expression meta-analysis of predicted microRNA targets identifies a diagno...Yu Liang
This study identifies a 17-gene expression signature that can accurately classify lung adenocarcinoma and squamous cell carcinoma, the two major histological subtypes of lung cancer. The signature was developed by predicting microRNA target genes, filtering them based on gene ontology terms and ability to classify cancers, and analyzing gene expression data from multiple datasets. When validated in independent datasets, the signature correctly classified 87% of adenocarcinoma and 82% of squamous cell carcinoma samples on average. Expression of the signature also showed potential for early lung cancer detection in bronchial epithelial cells from smokers.
This document describes a study investigating the role of the protein Morgana in breast cancer metastasis. The study found that knocking down Morgana impaired migration, invasion, and metastasis of breast cancer cells in vitro and in vivo. Mechanistically, Morgana was found to increase the transcriptional activity of NF-κB, leading to increased expression of metastasis-promoting genes like MMP-9. Overexpressing Morgana had the opposite effect of increasing NF-κB target gene expression. Therefore, Morgana appears to promote breast cancer metastasis by activating the NF-κB pathway and increasing expression of pro-metastatic genes.
This document summarizes key signaling pathways in muscle-invasive bladder carcinoma. It discusses molecular markers that indicate basal or luminal subtypes of bladder cancer, which differ in response to treatment. Basal cancers often overexpress EGFR and respond to chemotherapy, while luminal cancers involve alterations in genes like FGFR3, ERBB2/3 and are generally less aggressive. The document also reviews markers for cancer stem cells, receptor tyrosine kinase signaling pathways, cytoskeleton proteins, the PI3K-Akt-mTOR pathway, and VEGF/VEGFR pathways that are clinically significant for modeling and optimizing treatment of muscle-invasive bladder cancer.
miRNA Breast Cancer Prognosis -- Ingenuity SystemsNatalie Ng
1) The document describes research to develop microRNA prognostic signatures that can predict breast cancer metastasis and determine which patients would benefit from chemotherapy.
2) Through computational modeling of miRNA and mRNA expression data, the researcher identified 5-miRNA signatures for ER-positive and ER-negative breast cancer.
3) In vitro experiments on breast cancer cell lines validated that the expressions of miRNAs in the signatures correlated with metastatic characteristics like migration, invasion and proliferation as predicted by the computational models.
11.06.13 - 2013 NIH Research Festival PosterFarhoud Faraji
The study uses systems genetics to identify a network of co-expressed genes centered on Cnot2 that predicts breast cancer metastasis. Cnot2 overexpression regulates the expression of network genes and modulates metastatic potential in vivo. Small RNA sequencing revealed miR-3470b as an upstream regulator of the Cnot2 network by downregulating its hub genes. miR-3470b promotes a pro-metastatic transcriptional profile and increases metastasis in vivo, demonstrating it plays a key role in regulating the metastatic process.
Characterization of microRNA expression profiles in normal human tissuesYu Liang
This document describes a study that characterized the expression profiles of microRNAs (miRNAs) in 40 normal human tissues. The researchers used quantitative real-time PCR to measure the expression levels of 345 miRNAs. They found that tissues from similar anatomical locations or with related physiological functions tended to cluster together based on their miRNA expression profiles. Many miRNAs showed exclusive or preferential expression in certain tissue types. The genomic locations of miRNAs also correlated with their expression patterns, as miRNAs located near each other on chromosomes often showed coordinated expression. The study provided a global view of miRNA tissue distribution and their potential roles in regulating normal tissue physiology.
- Certain miRNAs, such as miR-21 and miR-34a, show potential as biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) as their expression levels correlate with cancer progression and patient survival.
- Inhibiting overexpressed miRNAs in PDAC, such as miR-21, miR-221 and miR-222, using antagomirs delivered via lipoplex nanoparticles reduced tumor cell proliferation, invasion and restored chemosensitivity in cell line studies.
- Epithelial-mesenchymal transition (EMT), which is regulated by transcription factors and miRNAs and promotes metastasis, plays an important role in PDAC development. Controlling pathways involved in EMT
This document reports on a study that identified cysteine-rich protein 2 (CRP2) as a new component of breast cancer cell invadopodia that promotes invasion and metastasis. The study found that CRP2 expression is higher in mesenchymal/invasive breast cancer cells and its expression level correlates with increased risk of metastasis in basal-like breast cancer patients. CRP2 was shown to localize to the actin core of invadopodia, where it bundles actin filaments. Knockdown of CRP2 reduced breast cancer cell invasion, matrix degradation, and MMP-9 expression/secretion. Ectopic expression of CRP2 in less invasive cells increased invasion. Depletion of CR
The document describes a study that integrated The Cancer Genome Atlas (TCGA) pan-cancer data with experimentally defined microRNA-target interactions from Argonaute Crosslinking Immunoprecipitation (AGO-CLIP) data to identify a coregulated "superfamily" of oncogenic microRNAs. Analysis revealed a pan-cancer microRNA superfamily consisting of the miR-17, miR-19, miR-130, miR-93, miR-18, miR-455 and miR-210 seed families that cotarget critical tumour suppressors through a central GUGC core motif. This microRNA superfamily was found to cotarget the phosphoinositide 3-kinase, TGFβ and p53 pathways in many
This document summarizes research on Cadm1, a gene that suppresses metastasis. Genetic analysis identified a locus on mouse chromosome 9 associated with metastasis. Cadm1 was validated as a metastasis-suppressing gene within this locus. Ectopic expression of Cadm1 reduced pulmonary metastasis in vivo, while knockdown increased metastasis. Cadm1 expression was associated with better survival in human breast cancer datasets. The mechanism of Cadm1's effect involves interaction with the cell-mediated immune system through proteins like CRTAM that activate CD8+ T cells and NK cells, reducing metastasis in an immune-dependent manner.
This document describes a study that conducted an RNA interference screening in breast cancer cells to identify epigenetic factors regulating the mesenchyme to epithelium transition (MET). Researchers designed a siRNA library targeting 729 chromatin modification genes and screened it in the mesenchymal breast cancer cell line MDA-MB-231. They identified 70 candidate genes involved in MET, including known genes like ZEB1, G9a, SMAD5 and SMARCD3, as well as DOT1L which has been implicated in MET. They also identified KAT5 as a novel gene linked to maintaining the mesenchymal phenotype for the first time. The screening approach involved measuring E-cadherin induction and cell
Michael's IUCRL Poster 2014 Close to Final with CDW editsMichael Araya
1) The study analyzed gene expression data from The Cancer Genome Atlas to identify genes that correlate with Amot in breast cancer and AmotL2 in thyroid cancer.
2) Pathway analysis revealed several cancer-related pathways that covaried with Amot levels in breast cancer, including Wnt signaling and TGF-beta signaling.
3) Genes that positively correlated with Amot in breast cancer and negatively correlated with AmotL2 in thyroid cancer were enriched for those involved in tumor growth, metastasis, and cancer stem cells.
This document discusses a study examining the roles of the transcriptional repressors Snail and Slug in mediating radioresistance and chemoresistance in ovarian cancer cells. The study finds that Snail and Slug contribute to resistance by 1) repressing p53-mediated apoptosis and 2) promoting the acquisition of stem-like characteristics in ovarian cancer cells. This allows cancer cells to survive radiation/chemotherapy stress and take on properties associated with cancer stem cells that can regenerate tumors. The study identifies many new direct gene targets of Snail and Slug through various genomic analyses and validates their roles in mediating resistance in ovarian cancer cell models.
This document summarizes research on analyzing differential miRNA-mRNA co-expression networks in colorectal cancer. The researchers analyzed paired expression data from cancer and normal tissues to identify changes in interactions. They found that cancer networks have decreased connectivity and identified differentially connected genes, including known cancer genes. Pathway analysis revealed an alteration in colorectal cancer tissues in the interplay between miRNAs and the eukaryotic translation initiation factor 3 complex, which is important for translation. Certain miRNAs were also identified as having many differentially co-expressed target mRNAs.
This document summarizes a study investigating the role of microRNA-302 in regulating retinal epithelial cell fate by targeting the TGF-β type II receptor. The study demonstrates that microRNA-302 promotes pluripotency in ARPE cells in vitro by regulating TGF-β signaling and epigenetic changes. It also shows that small molecules DZNEP and SB431542 can induce pluripotency by attenuating pathways involved in cell differentiation, supporting the potential for microRNAs and small molecules in regenerative medicine and therapeutics for diseases like diabetic retinopathy.
Sophisticated genomics-based tools will transform cancer care in the coming decade. This paper investigates what will drive this transformation in oncology. Next-generation sequencing (NGS) will play a key role by providing a deeper understanding of cancer's molecular complexity through genomic techniques. NGS allows researchers to sequence entire genomes, exomes, and RNA to identify biomarkers and explore features like single nucleotide variations, translocations, and copy number variations. While NGS provides powerful approaches, its application requires an understanding of each platform's capabilities and limitations to obtain reliable results.
Potentiality of a triple microRNA classifier: miR- 193a-3p, miR-23a and miR-3...Enrique Moreno Gonzalez
MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs offer great potential as cancer biomarkers. The objective of this study was to correlate the differential expression of miRNAs in tissue and blood in the identification of biomarkers for early detection of colorectal cancer (CRC).
This document describes a bioinformatics approach for prioritizing disease-causing human mitochondrial DNA mutations. It uses a "disease score" that averages the probabilities from six pathogenicity prediction methods to determine if a mutation is deleterious or benign. The approach was trained on 53 known disease-associated mutations and tested on 1872 observed mutations, achieving a disease score cutoff of 0.4311. Mutations meeting criteria of being rare, conserved, predicted pathogenic and occurring at low variability sites were prioritized. When tested on 21 tumor samples, 8/268 prioritized nonsynonymous mutations were tumor-specific, confirming the approach's ability to identify potentially pathogenic mutations.
This document summarizes a study investigating the role of microRNA-122 (miR-122) in regulating intrahepatic metastasis of hepatocellular carcinoma (HCC). The study found that miR-122 expression is significantly downregulated in HCC tumors with intrahepatic metastasis. Restoring miR-122 expression in metastatic HCC cell lines reduced in vitro migration, invasion, and tumor growth in vivo. Computational analysis identified multiple target genes of miR-122, including ADAM17, which was shown to be involved in metastasis. Silencing ADAM17 had similar effects as restoring miR-122, reducing in vitro and in vivo measures of metastasis. The study suggests that miR-122 acts as a tumor suppressor
This study analyzed 264 gastric cancers for mutations in exons 9 and 20 of the PIK3CA gene. PIK3CA mutations were found in 42 cases (16%), all heterozygous missense mutations. The most common mutation was H1047R in exon 20 (62% of mutations) and the second most common was Q546K in exon 9 (9.5% of mutations). A meta-analysis of 27 publications found that the ratio of exon 20 to exon 9 mutations varied by cancer type, being highest in gastric cancer. The exon mutation selectivity is a signature of the cancer type.
The study of genetic alterations of the signal transducing molecules and their role in the development and progression of Colorectal Cancer in Kashmir Valley
Pe gylated drug delivery systems for si rna drug development in cancer therapyDoriaFang
1) PEGylated drug delivery systems show potential for siRNA drug delivery, especially in cancer therapy.
2) siRNA works by degrading mRNA after transcription, preventing gene expression, and has advantages over chemotherapy like high safety and efficacy.
3) However, barriers remain for clinical use of siRNA in cancer including instability, difficulty entering cells, off-target effects, and potential immune activation. Developing delivery systems to transport siRNA into target cells is a major challenge.
Opportunities and challenges provided by crosstalk between signalling pathway...Anirudh Prahallad
This document summarizes opportunities and challenges in exploiting crosstalk between signaling pathways for cancer treatment. It discusses how inhibition of one pathway can activate a secondary survival pathway, conferring resistance. The review evaluates using genetic approaches to identify pathway crosstalk and develop combination therapies. It provides examples where targeting two interacting pathways showed stronger effects than single agents, including combinations of BRAF/EGFR inhibitors for BRAF mutant colon cancer and MEK/ERBB3 inhibitors for KRAS mutant cancers.
miRNAs in the spotlight: Making 'silent' mutations speak up.David W. Salzman
This document discusses the role of microRNAs (miRNAs) in disease. It describes two studies: 1) A human study showing that a silent mutation impairs miRNA binding, increasing Crohn's disease risk. This provides evidence that silent mutations can functionally impact miRNA regulation and cause disease. 2) A mouse study demonstrating tumor dependence on miR-21, highlighting the role of miRNAs as disease drivers. Targeting these miRNA drivers may help develop new drugs. The document argues that further investigation is needed into how genetic variants alter miRNA regulation and contribute to disease.
This document describes a bioinformatics tool that predicts gene expression in cancer using copy number alterations and methylation data as predictors in a linear model. The tool was created using data from The Cancer Genome Atlas and the R programming language. It analyzes specific cancers to identify oncogenes and tumor suppressor genes that are relevant to those cancers, and determines which genetic or epigenetic factors drive the expression of those genes. The tool provides comprehensive analysis of individual genes and ranks their relevance to different cancers. It allows researchers to efficiently understand disease-specific gene expression and identify additional genes involved in cancer.
1) The study compared genome-wide DNA methylation data from paired fresh-frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) colon tumor and normal tissue samples from 12 colorectal cancer patients.
2) They found reasonable correlation between FF and FFPE samples for individual loci and tissue types. However, tissue storage type (FF vs FFPE) was a more significant source of variation than tissue type (tumor vs normal).
3) There was poor concordance between differentially methylated loci detected in tumor vs normal comparisons between FF and FFPE samples, with only 7 of the top 50 loci being common between the two sample types.
This study compared remission rates in 5,848 rheumatoid arthritis patients from 24 countries using different definitions of remission. The overall remission rate varied substantially depending on the definition used, from 8.6% using the ACR definition to 19.6% using DAS28. Remission rates also varied considerably between countries. Regardless of the definition, factors associated with higher remission rates included male sex, higher education, shorter disease duration, fewer comorbidities, and regular exercise. The results indicate that reported remission rates need to be interpreted based on the specific definition of remission that was applied.
Este documento proporciona información sobre el cáncer de pulmón. Explica que el cáncer comienza en las células pulmonares y puede extenderse a otros órganos. Describe los tipos principales de cáncer de pulmón y las pruebas utilizadas para determinar el estadio o grado de avance de la enfermedad. Finalmente, resume los cuatro estadios principales del cáncer de pulmón de células no pequeñas en función del tamaño del tumor y su propagación a otros tejidos.
This document reports on a study that identified cysteine-rich protein 2 (CRP2) as a new component of breast cancer cell invadopodia that promotes invasion and metastasis. The study found that CRP2 expression is higher in mesenchymal/invasive breast cancer cells and its expression level correlates with increased risk of metastasis in basal-like breast cancer patients. CRP2 was shown to localize to the actin core of invadopodia, where it bundles actin filaments. Knockdown of CRP2 reduced breast cancer cell invasion, matrix degradation, and MMP-9 expression/secretion. Ectopic expression of CRP2 in less invasive cells increased invasion. Depletion of CR
The document describes a study that integrated The Cancer Genome Atlas (TCGA) pan-cancer data with experimentally defined microRNA-target interactions from Argonaute Crosslinking Immunoprecipitation (AGO-CLIP) data to identify a coregulated "superfamily" of oncogenic microRNAs. Analysis revealed a pan-cancer microRNA superfamily consisting of the miR-17, miR-19, miR-130, miR-93, miR-18, miR-455 and miR-210 seed families that cotarget critical tumour suppressors through a central GUGC core motif. This microRNA superfamily was found to cotarget the phosphoinositide 3-kinase, TGFβ and p53 pathways in many
This document summarizes research on Cadm1, a gene that suppresses metastasis. Genetic analysis identified a locus on mouse chromosome 9 associated with metastasis. Cadm1 was validated as a metastasis-suppressing gene within this locus. Ectopic expression of Cadm1 reduced pulmonary metastasis in vivo, while knockdown increased metastasis. Cadm1 expression was associated with better survival in human breast cancer datasets. The mechanism of Cadm1's effect involves interaction with the cell-mediated immune system through proteins like CRTAM that activate CD8+ T cells and NK cells, reducing metastasis in an immune-dependent manner.
This document describes a study that conducted an RNA interference screening in breast cancer cells to identify epigenetic factors regulating the mesenchyme to epithelium transition (MET). Researchers designed a siRNA library targeting 729 chromatin modification genes and screened it in the mesenchymal breast cancer cell line MDA-MB-231. They identified 70 candidate genes involved in MET, including known genes like ZEB1, G9a, SMAD5 and SMARCD3, as well as DOT1L which has been implicated in MET. They also identified KAT5 as a novel gene linked to maintaining the mesenchymal phenotype for the first time. The screening approach involved measuring E-cadherin induction and cell
Michael's IUCRL Poster 2014 Close to Final with CDW editsMichael Araya
1) The study analyzed gene expression data from The Cancer Genome Atlas to identify genes that correlate with Amot in breast cancer and AmotL2 in thyroid cancer.
2) Pathway analysis revealed several cancer-related pathways that covaried with Amot levels in breast cancer, including Wnt signaling and TGF-beta signaling.
3) Genes that positively correlated with Amot in breast cancer and negatively correlated with AmotL2 in thyroid cancer were enriched for those involved in tumor growth, metastasis, and cancer stem cells.
This document discusses a study examining the roles of the transcriptional repressors Snail and Slug in mediating radioresistance and chemoresistance in ovarian cancer cells. The study finds that Snail and Slug contribute to resistance by 1) repressing p53-mediated apoptosis and 2) promoting the acquisition of stem-like characteristics in ovarian cancer cells. This allows cancer cells to survive radiation/chemotherapy stress and take on properties associated with cancer stem cells that can regenerate tumors. The study identifies many new direct gene targets of Snail and Slug through various genomic analyses and validates their roles in mediating resistance in ovarian cancer cell models.
This document summarizes research on analyzing differential miRNA-mRNA co-expression networks in colorectal cancer. The researchers analyzed paired expression data from cancer and normal tissues to identify changes in interactions. They found that cancer networks have decreased connectivity and identified differentially connected genes, including known cancer genes. Pathway analysis revealed an alteration in colorectal cancer tissues in the interplay between miRNAs and the eukaryotic translation initiation factor 3 complex, which is important for translation. Certain miRNAs were also identified as having many differentially co-expressed target mRNAs.
This document summarizes a study investigating the role of microRNA-302 in regulating retinal epithelial cell fate by targeting the TGF-β type II receptor. The study demonstrates that microRNA-302 promotes pluripotency in ARPE cells in vitro by regulating TGF-β signaling and epigenetic changes. It also shows that small molecules DZNEP and SB431542 can induce pluripotency by attenuating pathways involved in cell differentiation, supporting the potential for microRNAs and small molecules in regenerative medicine and therapeutics for diseases like diabetic retinopathy.
Sophisticated genomics-based tools will transform cancer care in the coming decade. This paper investigates what will drive this transformation in oncology. Next-generation sequencing (NGS) will play a key role by providing a deeper understanding of cancer's molecular complexity through genomic techniques. NGS allows researchers to sequence entire genomes, exomes, and RNA to identify biomarkers and explore features like single nucleotide variations, translocations, and copy number variations. While NGS provides powerful approaches, its application requires an understanding of each platform's capabilities and limitations to obtain reliable results.
Potentiality of a triple microRNA classifier: miR- 193a-3p, miR-23a and miR-3...Enrique Moreno Gonzalez
MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs offer great potential as cancer biomarkers. The objective of this study was to correlate the differential expression of miRNAs in tissue and blood in the identification of biomarkers for early detection of colorectal cancer (CRC).
This document describes a bioinformatics approach for prioritizing disease-causing human mitochondrial DNA mutations. It uses a "disease score" that averages the probabilities from six pathogenicity prediction methods to determine if a mutation is deleterious or benign. The approach was trained on 53 known disease-associated mutations and tested on 1872 observed mutations, achieving a disease score cutoff of 0.4311. Mutations meeting criteria of being rare, conserved, predicted pathogenic and occurring at low variability sites were prioritized. When tested on 21 tumor samples, 8/268 prioritized nonsynonymous mutations were tumor-specific, confirming the approach's ability to identify potentially pathogenic mutations.
This document summarizes a study investigating the role of microRNA-122 (miR-122) in regulating intrahepatic metastasis of hepatocellular carcinoma (HCC). The study found that miR-122 expression is significantly downregulated in HCC tumors with intrahepatic metastasis. Restoring miR-122 expression in metastatic HCC cell lines reduced in vitro migration, invasion, and tumor growth in vivo. Computational analysis identified multiple target genes of miR-122, including ADAM17, which was shown to be involved in metastasis. Silencing ADAM17 had similar effects as restoring miR-122, reducing in vitro and in vivo measures of metastasis. The study suggests that miR-122 acts as a tumor suppressor
This study analyzed 264 gastric cancers for mutations in exons 9 and 20 of the PIK3CA gene. PIK3CA mutations were found in 42 cases (16%), all heterozygous missense mutations. The most common mutation was H1047R in exon 20 (62% of mutations) and the second most common was Q546K in exon 9 (9.5% of mutations). A meta-analysis of 27 publications found that the ratio of exon 20 to exon 9 mutations varied by cancer type, being highest in gastric cancer. The exon mutation selectivity is a signature of the cancer type.
The study of genetic alterations of the signal transducing molecules and their role in the development and progression of Colorectal Cancer in Kashmir Valley
Pe gylated drug delivery systems for si rna drug development in cancer therapyDoriaFang
1) PEGylated drug delivery systems show potential for siRNA drug delivery, especially in cancer therapy.
2) siRNA works by degrading mRNA after transcription, preventing gene expression, and has advantages over chemotherapy like high safety and efficacy.
3) However, barriers remain for clinical use of siRNA in cancer including instability, difficulty entering cells, off-target effects, and potential immune activation. Developing delivery systems to transport siRNA into target cells is a major challenge.
Opportunities and challenges provided by crosstalk between signalling pathway...Anirudh Prahallad
This document summarizes opportunities and challenges in exploiting crosstalk between signaling pathways for cancer treatment. It discusses how inhibition of one pathway can activate a secondary survival pathway, conferring resistance. The review evaluates using genetic approaches to identify pathway crosstalk and develop combination therapies. It provides examples where targeting two interacting pathways showed stronger effects than single agents, including combinations of BRAF/EGFR inhibitors for BRAF mutant colon cancer and MEK/ERBB3 inhibitors for KRAS mutant cancers.
miRNAs in the spotlight: Making 'silent' mutations speak up.David W. Salzman
This document discusses the role of microRNAs (miRNAs) in disease. It describes two studies: 1) A human study showing that a silent mutation impairs miRNA binding, increasing Crohn's disease risk. This provides evidence that silent mutations can functionally impact miRNA regulation and cause disease. 2) A mouse study demonstrating tumor dependence on miR-21, highlighting the role of miRNAs as disease drivers. Targeting these miRNA drivers may help develop new drugs. The document argues that further investigation is needed into how genetic variants alter miRNA regulation and contribute to disease.
This document describes a bioinformatics tool that predicts gene expression in cancer using copy number alterations and methylation data as predictors in a linear model. The tool was created using data from The Cancer Genome Atlas and the R programming language. It analyzes specific cancers to identify oncogenes and tumor suppressor genes that are relevant to those cancers, and determines which genetic or epigenetic factors drive the expression of those genes. The tool provides comprehensive analysis of individual genes and ranks their relevance to different cancers. It allows researchers to efficiently understand disease-specific gene expression and identify additional genes involved in cancer.
1) The study compared genome-wide DNA methylation data from paired fresh-frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) colon tumor and normal tissue samples from 12 colorectal cancer patients.
2) They found reasonable correlation between FF and FFPE samples for individual loci and tissue types. However, tissue storage type (FF vs FFPE) was a more significant source of variation than tissue type (tumor vs normal).
3) There was poor concordance between differentially methylated loci detected in tumor vs normal comparisons between FF and FFPE samples, with only 7 of the top 50 loci being common between the two sample types.
This study compared remission rates in 5,848 rheumatoid arthritis patients from 24 countries using different definitions of remission. The overall remission rate varied substantially depending on the definition used, from 8.6% using the ACR definition to 19.6% using DAS28. Remission rates also varied considerably between countries. Regardless of the definition, factors associated with higher remission rates included male sex, higher education, shorter disease duration, fewer comorbidities, and regular exercise. The results indicate that reported remission rates need to be interpreted based on the specific definition of remission that was applied.
Este documento proporciona información sobre el cáncer de pulmón. Explica que el cáncer comienza en las células pulmonares y puede extenderse a otros órganos. Describe los tipos principales de cáncer de pulmón y las pruebas utilizadas para determinar el estadio o grado de avance de la enfermedad. Finalmente, resume los cuatro estadios principales del cáncer de pulmón de células no pequeñas en función del tamaño del tumor y su propagación a otros tejidos.
El documento describe el papel de la Organización Mundial de la Salud (OMS) en la transición de la salud internacional a la salud global. Explica que la OMS pasó de ser el líder indiscutible de la salud internacional después de 1948 a enfrentar una crisis de presupuesto y poder en 1998, frente a nuevos actores influyentes. También sugiere que la OMS comenzó a redefinirse como coordinador y líder de iniciativas globales de salud como estrategia de supervivencia ante este contexto político cambiante.
El documento promueve el café Express de Perú, afirmando que es el mejor café del mundo. Ofrece una rica esencia y aroma que cautivará el paladar. Incluye gráficos que muestran las ventas crecientes de Café Express y una lista de la dirección y sucursales a nivel mundial de la compañía.
Este documento presenta una introducción al Análisis de Situación de Salud Local. Explica conceptos clave como determinantes sociales de salud, inequidades en salud e identificación de problemas de salud. Además, describe los componentes, etapas y proceso de elaboración de un Análisis de Situación de Salud Local, incluyendo la recolección de información, priorización de problemas y territorios vulnerables, y propuestas de líneas de acción.
1) The aqueous extract of Sida rhombifolia ssp. retusa roots showed hepatoprotective effects against liver damage induced by thioacetamide and allyl alcohol in rats.
2) Pretreatment with the extract significantly reduced elevated liver enzymes and normalized liver weight and volume caused by thioacetamide toxicity. The extract also prevented decreases in body weight and reduced necrosis caused by allyl alcohol.
3) The study demonstrates that the roots of Sida rhombifolia ssp. retusa have potent hepatoprotective properties against chemically-induced liver damage in rats.
Este documento explica lo que es la atención primaria de la salud y lo que no es, a casi 35 años de la Conferencia de Alma-Ata. La atención primaria de la salud fue concebida como una estrategia para lograr la meta social de "Salud para todos", pero ha sido malinterpretada como atención básica o servicios insuficientes para los pobres. El documento busca aclarar el verdadero significado e importancia de la atención primaria de la salud para abordar las inequidades sociales y de sal
El documento describe un caso de trisomía parcial del cromosoma 1 en una niña de 6 meses causada por una translocación balanceada en la madre. Se presentan los rasgos clínicos de la paciente como retraso en el crecimiento, retraso psicomotor y anomalías faciales y óseas. El estudio cromosómico reveló que la madre tenía una translocación equilibrada entre los cromosomas 1 y 6, transmitiendo a la hija una trisomía parcial del cromosoma 1.
Este documento resume el estado actual del tratamiento del cáncer de pulmón. Se divide el cáncer de pulmón en dos grupos principales (carcinoma microcítico y no microcítico) y se discute el enfoque terapéutico individualizado para cada grupo según el estadio y otros factores. También analiza nuevos objetivos terapéuticos como los inhibidores del EGFR y la importancia de la medicina molecular para una personalización aún mayor del tratamiento.
Este documento presenta una guía clínica para el diagnóstico y tratamiento del cáncer de pulmón. Describe el proceso de diagnóstico, que incluye la sospecha clínica, estudios iniciales como TAC y análisis de sangre, y técnicas para confirmar el diagnóstico como broncoscopia y biopsia. Explica los conceptos de operabilidad, resecabilidad y estadificación, y proporciona recomendaciones sobre el tratamiento quirúrgico, sistémico y radioterápico seg
Este documento proporciona información sobre el cáncer de pulmón, incluyendo sus causas, tipos, factores de riesgo, pruebas de diagnóstico y pronóstico. Explica que el tabaco es la principal causa del cáncer de pulmón y describe los dos tipos principales, de células pequeñas y no pequeñas. Además, detalla los exámenes necesarios como tomografías, broncoscopias y biopsias para determinar la etapa del cáncer y el tratamiento apropiado.
Este documento describe el cáncer de pulmón microcítico (células pequeñas), incluyendo su definición, estadísticas, factores de riesgo y detalles sobre la anatomía pulmonar. Representa alrededor del 10-15% de los cánceres de pulmón y se asocia principalmente con el humo del tabaco. Las tasas son más altas en hombres que en mujeres y aumentan con la edad. Otros factores de riesgo incluyen la exposición a radón, asbesto u otras sustancias químicas
Trupti Nandkishor Gaikwad is a mechanical engineer seeking a position that allows her to fully utilize her skills and contribute to success. She has a B.E. in Mechanical Engineering from Sant Gadge Baba Amravati University with over 66% average. Her work experience includes a role as a Design Engineer at V Engineering. She is proficient in CAD software and has participated in university competitions and student associations.
El documento describe las diferentes etapas del desarrollo embrionario humano desde la fecundación hasta el nacimiento. Comienza con la unión del óvulo y el espermatozoide, seguido de la división celular que forma el embrión. Luego ocurre la gastrulación donde se forman las tres capas germinales. Finalmente, en la etapa de organogénesis los órganos se diferencian a partir de estas capas a lo largo de las 40 semanas de gestación, culminando con el nacimiento.
Presentación desarrollo post natal dianaDiana Ortiz
El documento describe las diferentes etapas del desarrollo humano, incluyendo el periodo neonatal, la infancia, la niñez, la adolescencia, la adultez y la senectud. Cada etapa se caracteriza por cambios físicos, cognitivos y emocionales específicos que ocurren en rangos de edad determinados.
Este documento presenta una introducción a los sistemas nacionales de salud, políticas de salud y reforma de salud en el Perú. Explica los diferentes modelos de sistemas de salud como el sistema universal de salud, el sistema de seguridad social y el sistema de salud liberal. También describe los componentes clave de un sistema de salud como la política, el modelo de financiamiento y el modelo de atención. Finalmente, analiza los desafíos del sistema de salud peruano y las líneas de política de salud del país.
Este documento presenta una guía clínica para el diagnóstico y tratamiento del cáncer de pulmón. Inicialmente se realizan estudios como radiografía de tórax, TAC, análisis de sangre y electrocardiograma. Posteriormente, se confirma el diagnóstico mediante broncoscopia o biopsia, y se clasifica el tumor según el sistema TNM. Finalmente, se evalúa la operabilidad y resecabilidad del paciente, y de no ser candidato a cirugía se consideran opciones de tratamiento sistémico
El documento trata sobre salud y sistemas de salud. Explica la evolución del concepto de salud desde 1946 hasta la actualidad, abarcando definiciones de salud pública, sus objetivos y actividades. También cubre las funciones esenciales de la salud pública, la relación entre salud pública y desarrollo del país, y define los sistemas de salud, sus objetivos, principios, factores condicionantes y modelos.
This document summarizes recent research on the role of noncoding RNAs, such as microRNAs and long noncoding RNAs, in prostate cancer progression and castration-resistant prostate cancer. It discusses how some noncoding RNAs are regulated by the androgen receptor and promote tumor growth by influencing processes like apoptosis, cell cycle, and cell invasion. The expression levels of certain microRNAs have been associated with prostate cancer diagnosis, aggressiveness, and treatment resistance. Integrative analyses of androgen receptor binding sites and regulated transcripts have provided new insights into the complex molecular mechanisms driven by noncoding RNAs in prostate cancer.
This document summarizes recent research on the role of noncoding RNAs, such as microRNAs and long noncoding RNAs, in prostate cancer progression and castration-resistant prostate cancer. It discusses how some noncoding RNAs are regulated by the androgen receptor and promote tumor growth by influencing processes like apoptosis, cell cycle, and epigenetic regulation. The expression levels of certain microRNAs have been associated with prostate cancer diagnosis, aggressiveness, and treatment resistance. Integrative analyses of androgen receptor binding sites and regulated transcripts have provided new insights into prostate cancer's molecular mechanisms.
2020 regulatory mechanism of micro rna expression in cancerAntar
This document summarizes how microRNA (miRNA) expression is deregulated in cancer. It discusses how genetic and epigenetic alterations can dysregulate miRNA expression at the transcriptional and post-transcriptional levels. Specifically, it describes how transcription factors like p53, RREB1, C/EBPβ, and c-Myc can modulate miRNA expression and impact cancer processes. It also explains how epigenetic changes like DNA methylation and histone modifications at miRNA gene promoters can alter miRNA expression patterns in cancer. Understanding these regulatory mechanisms of miRNA expression is important for elucidating their roles in cancer pathogenesis.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and affect multiple cellular processes. Dysregulation of miRNAs is common in cancer and can impact cancer hallmarks like sustained proliferation, evading growth suppression, resisting cell death, and activating invasion and metastasis. Certain miRNAs are considered oncogenes when their expression is increased in tumors, while others act as tumor suppressors when their expression is decreased. Altered miRNA expression and biogenesis machinery defects contribute to cancer development and progression. miRNAs also show potential as cancer biomarkers and therapeutic targets.
Computational analysis on microRNA in malariaGregorio Rangel
This document discusses predicting host microRNAs (miRNAs) that modulate genes associated with malaria pathogenesis as potential biomarkers. It describes using bioinformatics tools miRanda and TargetScan to predict miRNAs that regulate genes related to severe malaria (CD36, IFN-γ, TLR4, PRR15). The results showed several miRNAs predicted to regulate these genes, including miR-203a-3p.1, miR-146, miR-155-5p, which may serve as biomarkers for disease progression. The document concludes that further study of circulating miRNAs associated with significant host genes is needed.
MicroRNAs are small non-coding RNAs that regulate gene expression. They were first discovered in 1993 in C. elegans. Since then, thousands have been identified in humans. MicroRNAs play roles in many diseases including cancer, where they can act as oncogenes or tumor suppressors. They have also been linked to other diseases like cardiovascular disease and neurodegenerative disorders. Circulating microRNAs in blood plasma/serum show potential as non-invasive biomarkers for diseases since they are stable in microparticles and exosomes and can be easily detected using sensitive PCR methods.
MicroRNAs play important roles in regulating key cellular processes like the cell cycle, apoptosis, and differentiation by targeting oncogenes and tumor suppressor genes. Certain microRNAs are commonly misexpressed in cancers and can serve as diagnostic or prognostic biomarkers. Some microRNAs act as oncogenes by being overexpressed in cancers, making them potential therapeutic targets, while other underexpressed microRNAs like let-7 have tumor suppressive properties and may be developed as cancer therapies. MicroRNAs therefore represent promising candidates for improving current approaches to cancer treatment and diagnosis.
This systematic review and meta-analysis examines the prognostic significance of microRNAs (miRNAs) in melanoma patients. Twenty-four studies across eight countries involving 2,669 melanoma patients were included. Sixteen studies reporting on the association between 25 miRNA expression levels and patient survival outcomes were eligible for meta-analysis. The pooled hazard ratio for up- and downregulated miRNA expression was 1.043, indicating a 4.3% increased likelihood of death. Subgroup analysis found miRNA10b, miRNA16 and miRNA21 expressions correlated with poor prognosis. The review aims to determine the prognostic roles and mean effect sizes of miRNAs to help predict patient outcomes and guide clinical decision making.
This systematic review and meta-analysis examines the prognostic value of microRNAs (miRNAs) in stage II colorectal cancer patients. Eighteen studies were included for analysis. The pooled hazard ratio for death in stage II colorectal cancer patients was 1.90, indicating upregulation of miRNAs is associated with worse prognosis. Subgroup analyses found individual miRNAs like miR21, miR215, miR143-5p and miR106a were also associated with worse prognosis when upregulated. The study aims to identify miRNAs that could serve as biomarkers to predict prognosis and guide treatment decisions like use of adjuvant chemotherapy in stage II colorectal cancer.
MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression and play an important role in lung cancer. Profiling of miRNA expression in lung tumors has identified specific miRNAs that are upregulated or downregulated and correlate with patient outcomes. Certain miRNAs are connected to mutational status, like miRNA-155 which is increased in double negative KRAS and EGFR tumors. Integrating miRNA signatures could help with diagnostic and treatment decisions for lung cancer.
This document reviews the role of microRNAs (miRNAs) in the occurrence and development of esophageal squamous cell carcinoma (ESCC). It summarizes that various miRNAs have been found to be dysregulated in ESCC and can function either as tumor suppressors or oncogenes by targeting different genes involved in processes like cell proliferation, apoptosis and invasion. Specifically, it provides tables listing miRNAs that have been identified as tumor suppressors and oncogenes in ESCC, along with their biological effects and target genes. The document aims to enhance understanding of the molecular mechanisms by which miRNAs contribute to the progression of ESCC.
paraphrase the review in your own wordsThe tumor suppressor PTEN .pdfarihantgiftgallery
paraphrase the review in your own words?
The tumor suppressor PTEN (phosphatase and tensin homolog deleted from chromosome 10), is
a lipid phosphatase that converts phosphatidylinositol-3, 4, 5- triphosphate (PIP3) into
phosphatidylinositol (4, 5)- diphosphate (PIP2). PTEN is well-known as the most highly mutated
tumor suppressor gene in the p53-post era [66, 67]. Recently, three papers by Nadav Bar and
Rivka Dikstein, Linhua Liu and colleagues, and Laura Poliseno and colleagues, have
demonstrated that PTEN was a bona fide target of miR-22 in a small cohort of cancer cell lines
that are driven from breast cancer, cervical cancer, prostate cancer, and bronchial epithelial
cancer. These studies contradict a uniform role of miR-22, indicating that under certain
circumstances, miR-22 may function as an oncogene because of its antagonistic effects on tumor
suppressive PTEN signaling [26, 68, 69] (Fig. 3). Using various miRNA target prediction
programs and/or RNAhybrid program for evaluating the minimum free energy hybridization,
these three groups all found that miR-22-PTEN was a high scoring miRNA-target pair. Enforced
or reduced expression of miR-22 in human HEK293T, cervical cancer HeLa and breast cancer
MCF-7 cell lines (Nadav Bar and Rivka Dikstein), anti-benzo[a]pyrene-7, 8-diol-9, 10-epoxide
(anti-BPDE)-induced transformed human bronchial epithelial cancer cell line 16HBE-T (Linhua
Liu and colleagues) and prostate cancer cell line DU145 (Laura Poliseno and colleagues),
revealed that miR-22 negatively regulated PTEN protein expression. Intriguingly, an inverse
correlation between miR-22 and PTEN mRNA expression has been presented by Poliseno et al.,
while Liu et al. found that there was no change of PTEN mRNA expression regardless of miR-
22 levels. A similarly inverse association of miR-22 and J. Xiong PTEN protein levels was
observed in 16HBE-T and its parental normal cell line16HBE (Linhua Liu and colleagues), and
in several prostate cancer cell lines, prostate cell lines and a prostate tumor tissue microarray
(Laura Poliseno and colleagues). Furthermore, the mature levels of miR-22 were significantly
increased in these tumor cells versus their normal counterparts. In line with this result, a direct
correlation between miR-22 expression and phosphorylated AKT or between the expression of
miR- 22 and that of DICER was also identified by Laura Poliseno and colleagues. These three
groups all showed that an intact binding site at the 3’UTR of PTEN mRNA was required for
miR-22 targeting. Functional analyses showed that miR-22 could induce apoptosis, inhibited
colony formation and suppressed motility of bronchial epithelial cancer cells (Linhua Liu and
colleagues), and intrinsically promote prostate cancer cell growth and tumorigenesis in tumor-
bearing nude mice (Laura Poliseno and colleagues). Subsequently, the influence of miR-22 on
the downstream signaling of PTEN was tested. Bar et al. showed that miR-22 could stimulate
AKT activity, and i.
1. The study found that ADAM8, a protein highly expressed in triple-negative breast cancers, regulates the expression of miRNAs, including miR-720.
2. Experiments showed that ADAM8 induces miR-720 expression via activation of the β1-integrin/ERK signaling pathway.
3. Modulating miR-720 levels in triple-negative breast cancer cells revealed that miR-720 promotes migratory and invasive abilities, suggesting it plays a role in the aggressive phenotype driven by ADAM8.
This document summarizes a scientific article about overcoming limitations in sample material for miRNA biomarker discovery. It discusses how miRNAs have potential as diagnostic, prognostic, and theranostic biomarkers but valuable sample types like laser-captured samples or circulating tumor cells often have insufficient amounts of material for full miRNA profiling. The article presents an integrated PCR-based system that reduces the sample amount needed for full miRNA profiling by several orders of magnitude, enabling detailed analysis of even the smallest samples. This advance opens up new possibilities for biomarker development using hard-to-obtain sample types.
- miR-449b expression was significantly decreased in human CRC tissues and cell lines compared to normal tissues, and was even lower in metastatic CRC tissues.
- Forced expression of miR-449b in CRC cells significantly inhibited cell migration and invasion in vitro.
- miR-449b was found to negatively regulate MMP2 in CRC cells, and overexpression of MMP2 reversed the inhibitory effects of miR-449b on cell invasion and migration.
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression. The document summarizes miRNA biogenesis, function, relevance to human health, and future directions for miRNA research. Specifically, it describes how miRNAs are transcribed from DNA and processed through several steps by protein complexes into mature miRNAs that bind to messenger RNAs to inhibit translation or promote degradation. Hundreds of miRNAs have been found in humans, and each may target hundreds of mRNAs. Dysregulation of miRNAs has been linked to diseases like cancer, heart disease, and neurological disorders. Continued research on miRNAs may reveal new insights into gene regulation and disease pathways.
The role of selected microRNAs (miRNAs) in the negative regulation of pediatr...Ashtyn Zapletal
This document discusses the role of microRNAs (miRNAs) in retinoblastoma progression. It found that miRNA-188-5p was upregulated in retinoblastoma tissue and promotes cell motility via the Wnt/β-catenin signaling pathway. miRNA-21 levels were also increased and inhibition decreased cell migration and invasion through the PTEN/PI3K/AKT pathway. Conversely, miRNA-24 was downregulated in retinoblastoma tissue and inversely correlated with MYC levels, implicating these miRNAs in retinoblastoma progression through various biochemical pathways.
SiRNA Delivery for Cancer Therapy: Challenges and Future Perspective by Suvadeep Sen in Advancements in Bioequivalence & Bioavailability
https://crimsonpublishers.com/abb/fulltext/ABB.000518.php
Similar to Art%3 a10.1186%2fs12935 015-0185-1 (20)
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...Sérgio Sacani
Context. The observation of several L-band emission sources in the S cluster has led to a rich discussion of their nature. However, a definitive answer to the classification of the dusty objects requires an explanation for the detection of compact Doppler-shifted Brγ emission. The ionized hydrogen in combination with the observation of mid-infrared L-band continuum emission suggests that most of these sources are embedded in a dusty envelope. These embedded sources are part of the S-cluster, and their relationship to the S-stars is still under debate. To date, the question of the origin of these two populations has been vague, although all explanations favor migration processes for the individual cluster members. Aims. This work revisits the S-cluster and its dusty members orbiting the supermassive black hole SgrA* on bound Keplerian orbits from a kinematic perspective. The aim is to explore the Keplerian parameters for patterns that might imply a nonrandom distribution of the sample. Additionally, various analytical aspects are considered to address the nature of the dusty sources. Methods. Based on the photometric analysis, we estimated the individual H−K and K−L colors for the source sample and compared the results to known cluster members. The classification revealed a noticeable contrast between the S-stars and the dusty sources. To fit the flux-density distribution, we utilized the radiative transfer code HYPERION and implemented a young stellar object Class I model. We obtained the position angle from the Keplerian fit results; additionally, we analyzed the distribution of the inclinations and the longitudes of the ascending node. Results. The colors of the dusty sources suggest a stellar nature consistent with the spectral energy distribution in the near and midinfrared domains. Furthermore, the evaporation timescales of dusty and gaseous clumps in the vicinity of SgrA* are much shorter ( 2yr) than the epochs covered by the observations (≈15yr). In addition to the strong evidence for the stellar classification of the D-sources, we also find a clear disk-like pattern following the arrangements of S-stars proposed in the literature. Furthermore, we find a global intrinsic inclination for all dusty sources of 60 ± 20◦, implying a common formation process. Conclusions. The pattern of the dusty sources manifested in the distribution of the position angles, inclinations, and longitudes of the ascending node strongly suggests two different scenarios: the main-sequence stars and the dusty stellar S-cluster sources share a common formation history or migrated with a similar formation channel in the vicinity of SgrA*. Alternatively, the gravitational influence of SgrA* in combination with a massive perturber, such as a putative intermediate mass black hole in the IRS 13 cluster, forces the dusty objects and S-stars to follow a particular orbital arrangement. Key words. stars: black holes– stars: formation– Galaxy: center– galaxies: star formation
PPT on Alternate Wetting and Drying presented at the three-day 'Training and Validation Workshop on Modules of Climate Smart Agriculture (CSA) Technologies in South Asia' workshop on April 22, 2024.
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptxshubhijain836
Centrifugation is a powerful technique used in laboratories to separate components of a heterogeneous mixture based on their density. This process utilizes centrifugal force to rapidly spin samples, causing denser particles to migrate outward more quickly than lighter ones. As a result, distinct layers form within the sample tube, allowing for easy isolation and purification of target substances.
(June 12, 2024) Webinar: Development of PET theranostics targeting the molecu...Scintica Instrumentation
Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead.
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdfSelcen Ozturkcan
Ozturkcan, S., Berndt, A., & Angelakis, A. (2024). Mending clothing to support sustainable fashion. Presented at the 31st Annual Conference by the Consortium for International Marketing Research (CIMaR), 10-13 Jun 2024, University of Gävle, Sweden.
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptxgoluk9330
Ahota Beel, nestled in Sootea Biswanath Assam , is celebrated for its extraordinary diversity of bird species. This wetland sanctuary supports a myriad of avian residents and migrants alike. Visitors can admire the elegant flights of migratory species such as the Northern Pintail and Eurasian Wigeon, alongside resident birds including the Asian Openbill and Pheasant-tailed Jacana. With its tranquil scenery and varied habitats, Ahota Beel offers a perfect haven for birdwatchers to appreciate and study the vibrant birdlife that thrives in this natural refuge.
2. genomic regions or in fragile sites. Microarray expres-
sion data from a wide spectrum of cancer tissues/cells
have shown that aberrant miRNA expression is a rule ra-
ther than exception. The involvement and the role
played by miRNAs in many types of cancers were re-
ported in different types of cancers, including breast,
colon, gastric, lung, prostate and thyroid [20-24]. The
peer-reviewed scientific literature on miRNAs is huge
and indicated by ~15,943 PubMed hits as of March 2015
and, their role in cancer is very diverse both in terms of
the disease and experimental approaches used by the in-
vestigators. Although the overwhelming majority of pub-
lished papers focus on individual mRNA target, most
miRNAs can exert their effects by targeting multiple
mRNAs, some of which may reside in the same cellular
pathway. Some studies have also shown that there were re-
dundant with distinct sequences which can repress the
same target mRNA [25]. Mouse models featuring miRNA
overexpression or ablation have demonstrated causal links
between miRNAs and cancer development [26,27].
Bioinformatics methods to predict paradigms
The bioinformatics methods which are currently used to
predict paradigms suggested that the interaction of miR-
NAs with their targets (candidate mRNAs) depends on
the sequence, and evolutionary conservation [28,29].
Such methods identifies tens or hundreds of targets for
each miRNA: however, the false positive rates were re-
ported to be high [30]. Therefore, investigations examin-
ing the gain and loss of function of miRNAs are still
needed to confirm the predictions. Evaluation of the as-
sociation between a particular miRNA to a specific type
of cancer is additionally complicated by the genetic di-
versity of tumors, and in cell lines derived from different
tumors. A particular miRNA may have exhibited its
oncogenic function in some types of cancers whereas
the same miRNA was reported to act as a tumor sup-
pressor in other cancers. Some such examples include:
(i) miR-29, specifically miR-29a/-b/-c was reported as an
oncogene in breast cancer while the same miRNA-29
acted as a tumor-suppressor gene in lung tumors
[31,32]; (ii) loss of miR-23b conferred proliferative ad-
vantage and promoted bladder cancer cell migration and
invasion [33] while knocking down the expression of
same miRNA-23b in renal cell carcinoma (RCC) cell
lines induced apoptosis and reduced invasive capabilities
[34]. One possible explanation is that the same miRNA
can participate in distinct pathways, having different ef-
fects on cell survival, growth and proliferation that are
dependent on the cell type and pattern of gene expres-
sion. Furthermore, the potential for miRNA-mediated
regulation of gene expression is enormous since ~60% of
Figure 1 MicroRNA biogenesis pathways and their regulation: a schematic representation depicting the miRNA biogenesis pathway. The
primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA by the microprocessor complex Drosha-DGC8 in the
nucleus. The resulting precursor hairpin, the pre-miRNA, is exported from the nucleus by exportin-5-Ran-GTP. In the cytoplasm, the RNase Dicer form
complex with the double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to its mature length. The functional strand of the mature
miRNA is loaded together with Argonaute (Ago2) proteins into the RNA-induced silencing complex (RISC), where it targets mRNAs through mRNA
cleavage, deadenylation or translational repression, where as passenger strand (3′———————5′) is degraded.
Reddy Cancer Cell International (2015) 15:38 Page 2 of 6
3. mRNAs are predicted to be under the control of miR-
NAs [35]. Hence, it is imperative to verify the phenotype
and function of miRNA in appropriate animal and hu-
man cancer cell models.
Abnormal expression of miRNA
There were several reports indicating widespread disrup-
tion of miRNA expression levels in numerous diseases, in-
cluding cancer. Tumor tissues and cultured tumor cells
often exhibit significantly reduced expression levels of ma-
ture miRNAs [36]. Different mechanisms for the aberrant
expression of miRNA were documented. Three of them,
viz., (i) genetic alterations and single nucleotide poly-
morphism (SNP), (ii) epigenetic silencing and (iii) defects
in the miRNA biogenesis pathway, are discussed below.
(i) Genetic alterations and SNP: Complete mapping of
human miRNA genes revealed that a great majority
of the miRNAs were associated with fragile sites,
cancer-specific translocation breakpoints, repetitive
sequences and CpG islands [37]. However, some
studies have indicated such association is not
straight-forward and appears to be dependent on
the specific type of cancer [38]. Furthermore, the
existence of polymorphism in single nucleotides
(SNPs) is widely known and, evidence has been
presented suggesting the influence of SNPs on
miRNA targets in cancer-related pathways [39].
A gain in function due to SNP may enhance its
interaction with miRNA target and thus, enhance
its regulatory function such as a tumor suppressor
gene. In contrast, loss in function due to SNP may
result in increased expression of miRNA, which
then acts as an oncogene [40]. Additionally, SNPs in
target sites of miRNAs may also result in the escape of
degradation by miRNA [41]. All these observations
suggested that SNPs may be one of the contributing
factors in the regulation of biogenesis and
functionality of miRNAs.
(ii)Epigenetic regulation of miRNA expression: Several
research groups have investigated whether
epigenetics, i.e., hyper- or hypo-methylation (an
early event in carcinogenesis), play a role and
influence the activity of miRNA genes [42-44] since
the expression of miRNA genes, especially those
located near CpG islands, tends to be affected more
readily by methylation processes [42,43,45]. In
scientific literature, there were several examples of
DNA methylation processes influencing the activity
of miRNAs. Some such examples were as follows.
(i) The comparative analysis data in colon cancer
cell line indicated that the expression of about 10%
miRNAs tested were regulated by DNA methylation
and that partial methylation reductions were not
sufficient for the recovery of miRNA [46]. (ii) Screening
investigations in colorectal cancers identified
(a) epigenetic silencing of miR-34b and miR-34c due to
hyper-methylation of neighboring CpG islands and
(b) alteration in the methylation process affected miR-9
family genes [47]. (iii) Methylation of miR-9-1 was
reportedly associated with lymph node metastasis in
colorectal cancer cells (CRC) [48]. (iv) Significant and
positive correlation between methylation of miR-200c/
141 and invasive capacity of breast cancer cells [49]. (v)
Methylation of miR-200c/141 is tightly associated with
the invasive capacity of breast cancer cells [49]. (vi) In
non-small cell lung cancer, promoter methylation was
related with loss of miR-200c expression which in turn
was associated with poor differentiation, lymph node
metastasis and weaker E-cadherin expression [50]. In
addition to DNA methylation, histone acetylation was
also reported to be another epigenetic phenomenon in
deregulated cancers. In breast cancer cells, histone
deacetylase inhibition was shown to result in
alteration in miRNA levels [51]. In bladder cancer cells,
a combined treatment with 5-aza-2′-deoxycytidine
(5-Aza-CdR) and histone deacetylase (HDAC) inhibitor
4-phenylbutyric acid (PBA) had a significant effect on
multiple miRNAs among which miR-127 was most
differentially expressed [45]. Specific induction/ac-
tivation of miRNA-127 by 5-Aza-CdR and PBA
suppressed the transcription of the zinc-finger
repressor BCL6 gene and thus induced apoptosis in
human cancer cells [45].
(iii)Defects in the miRNA pathway: In humans, the
majority of miRNAs are encoded by introns of
non-coding or coding transcripts. However, some
miRNAs were reported to be encoded by exonic
regions. The genes controlling miRNA are often
clustered and transcribed as polycistronic messages
or excised from mRNAs [52]. The precise locations
of promoters for most miRNA genes are not yet
mapped but, they can be inferred from collective
analysis of CpG islands, RNA sequencing and
chromatin immune-precipitation followed by
ChIP-sequencing [53]. Numerous Pol-II associated
transcription factors were reported to activate or
repress several miRNA genes. The abundance of some
miRNAs were also shown to be regulated at the RNA
stability level [54]. Recently, Ser/Thr protein kinase/
endoribonuclease IRE1α has been shown to be
activated by endoplasmic reticulum stress and cleaved
some selected pre-miRNAs, such as pre-miR-17,
pre-miR-34a, pre-miR-96 and pre-miR125b, leading to
translational reduction in the pro-apoptotic caspase 2
[55]. Previous reports have also indicated that Myc
gene is responsible for up-regulating the oncogenic
miR-17-92 cluster. The principal effect of Myc
Reddy Cancer Cell International (2015) 15:38 Page 3 of 6
4. activation was the repressed expression of multiple
miRNA [56,57] as well as down-regulation of several
anti-proliferative, pro-apoptotic and tumor suppressor
effects such as let-7, miR15a/16-1, miRNA-26a and
miR-34 family members [58]. Similarly, activation of
Ras gene was shown to result in repression of the
miR-143/145 cluster in k-Ras mutant pancreatic
cancers [59]. The p53 tumor suppressor gene was
reported to regulate the expression of several
miRNAs, such as miR34, miR-200. miR 15/16, etc.
[60,61] and the miR34 family targets cyclin D and E2,
CDK4, CDK6, Myc and BCl2 all of which play a major
role in promoting cell proliferation, apoptosis and,
these observations suggested the possibility that
p53-induced miR-34 may negatively regulate cell
growth [60,62].
miRNA in cancer diagnosis and therapy
Microarray analysis of oligonucleotide miRNA is the most
commonly used high-throughput technique for the assess-
ment of the expression levels of hundreds of miRNA in a
large number of cancer-specific cell types [63,64]. Studies
using miRNA profiling have shown significantly different
miRNA profiles in cancer cells compared with those in
normal cells in the same tissue. Hierarchical clustering
analyses also indicated that miRNA signature profiling en-
abled the tumor tissue samples to be grouped into a spe-
cific origin. Several genome-wide profiling studies have
been performed on various types of cancers, such as breast,
chronic lymphocytic leukemia, colon, lung, glioblastoma
and thyroid papillary carcinoma, etc. [21,22,65-68]. Ana-
lysis of miRNAs in 76 breast cancer and 10 normal breast
tissue samples had identified significantly dysregulated
miR-125b, miR-145, miR-21 and miR-155: from such ana-
lysis, 15 such analyses could correctly predict whether the
sample was normal or tumor breast tissue [22]. In a separ-
ate and similar investigation using breast cancer tissue, let-
7d, miR-210 and miR-221 were found to be down-
regulated in the ductal carcinoma in situ while they were
up-regulated in the invasive transition [69].
Non-invasive and inexpensive methods
Researchers are focusing on the examination of body
fluids such as plasma, serum, urine and saliva to deter-
mine the circulating levels of miRNAs and to evaluate if
they can be used as diagnostic, prognostic and predictive
biomarkers in cancer. Such studies have attracted a great
deal of attention because of minimally invasive processes
to examine miRNA using qPCR. In the serum of pros-
tate cancer patients, the expression levels of pre-selected
oncogenic miR-26a, miR-195 and let-7i were shown to be
up-regulated compared to those in individuals with benign
prostate hyperplasia (BPH) [70]. Similarly, the prognostic
value of increased expression levels of circulating miR-141
and miR-375 correlating with low-risk through high-risk
and from localized to metastatic prostate cancer was doc-
umented [71,72]. The signature miRNAs, miR-28-3p,
miR-30c, miR-92a, miR-140-5p, miR-451 and miR660 in
the plasma were found to be deregulated 1–2 years prior
to diagnosis of lung cancer and thus, indicated their use in
prediction as well as diagnosis [73]. miR-27b, miR-158a,
miR-326 signature or miR-200c in the serum of colon can-
cer patients were found to be useful to identify metastatic
tumors [74,75]. The miR-125b and miR-155 levels in the
serum of breast cancer patients were found to be useful
for diagnosis, assessing chemotherapeutic response as well
as in prognosis [76,77]. Until recently, miRNA analyses
were performed using qRT-PCR and microarray-based ap-
proaches. NGS is now emerging as a cost-effective option
while bioinformatics analyses are no longer a major prob-
lem for continued usage [78,79].
Clinical trials
The increasing understanding of the molecular alter-
ations underlying carcinogenesis and cancer had created
opportunities to use miRNAs as diagnostic and prognos-
tic indicators. Many signature miRNAs have been identi-
fied, and their use has been increasingly investigated in
clinical trials in several countries including USA. For ex-
ample: (i) circulating miRNA are used in breast cancer
as biomarkers to examine therapeutic response (https://
clinicaltrials.gov/ct2/show/NCT01722851); (ii) miR-10b
is used in Glioma as biomarker to grade the tumor, sur-
vival and genotypic variation (https://clinicaltrials.gov/
ct2/show/NCT01849952); (iii) miR-29 family (miR-29a/-
b/-c) is used to investigate the role of Twist-1-mediated
metastasis in Head and neck squamous cell carcinoma
(https://clinicaltrials.gov/ct2/show/NCT01927354); (iv) cir-
culating levels of miRNAs are evaluated as biomarker of
response to treatment in Ovarian cancer (https://clinicaltrials.
gov/ct2/show/NCT01391351); (v) multiple miRNAs are
investigated to examine the response to chemotherapy in
Non-small-cell lung cancer (https://clinicaltrials.gov/ct2/
show/NCT00864266), etc.
Conclusion
So far, there have been significant scientific research
findings indicating the utility of miRNAs as biomarkers
for prediction, diagnosis and prognosis. Evidence is also
emerging suggesting that inhibition of oncogenic miR-
NAs or substitution of tumor suppressive miRNAs could
be used to develop novel treatment strategies. The exten-
sive information thus far available in the peer-reviewed
scientific publications has been extremely useful to pro-
vide guidance for further investigations. Comprehensive,
carefully designed, multi-centered, retrospective and pro-
spective studies involving large cohorts in the same and
independent laboratories/clinics comparing and validating
Reddy Cancer Cell International (2015) 15:38 Page 4 of 6
5. the data within a similar type of cancer are warranted.
Besides, investigations using minimally invasive methods
to collect blood, saliva and urine are extremely important
for the development of reliable and cost-effective miRNA-
based technology for routine use in the clinics for early
cancer diagnosis/detection and therapeutic assessment/
prognosis.
Abbreviations
miRNAs: microRNAs; RISC: RNA-induced silencing complex; UTR: The 3′
untranslated region; SNP: Single nucleotide polymorphism, 5-Aza-CdR,
5-aza-2′-deoxycytidine.
Competing interests
The authors declare that he has no competing interests.
Funding
This work is supported by the National Institute of Health through grant
number R21CA178152 and Department of Pathology, WSU.
Received: 2 December 2014 Accepted: 18 March 2015
References
1. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med.
2009;60:167–79.
2. Bruce JP, Hui AB, Shi W, Perez-Ordonez B, Weinreb I, Xu W, et al.
Identification of a microRNA signature associated with risk of distant
metastasis in nasopharyngeal carcinoma. Oncotarget. 2015;6:4537–50.
Epud ahead of print.
3. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer. 2006;6(4):259–69.
4. Jeansonne D, De Luca M, Marrero L, Lassak A, Pacifici M, Wyczechowska D,
et al. Anti-Tumoral Effects of miR-3189-3p in Glioblastoma. J Biol Chem.
2015;290:8067–80. Epud ahead of print.
5. Pinatel EM, Orso F, Penna E, Cimino D, Elia AR, Circosta P, et al. miR-223 is a
coordinator of breast cancer progression as revealed by bioinformatics
predictions. PLoS One. 2014;9(1):e84859.
6. Ben-Hamo R, Efroni S. MicroRNA regulation of molecular pathways as a
generic mechanism and as a core disease phenotype. Oncotarget.
2015;6(3):1594–604.
7. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z. Emerging roles of
microRNAs as molecular switches in the integrated circuit of the cancer cell.
RNA. 2009;15(8):1443–61.
8. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent
deletions and down-regulation of micro- RNA genes miR15 and miR16 at
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A.
2002;99(24):15524–9.
9. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al.
Detection of elevated levels of tumour-associated microRNAs in serum of
patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–5.
10. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell
differentiation and development. Nat Rev Genet. 2014;15(1):7–21.
11. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions
in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699–712.
12. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev
Biochem. 2012;81:145–66.
13. Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, et al. lncRNA directs cooperative
epigenetic regulation downstream of chemokine signals. Cell.
2014;159(5):1110–25.
14. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of
primary microRNAs by the Microprocessor complex. Nature.
2004;432(7014):231–5.
15. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha
initiates microRNA processing. Nature. 2003;425(6956):415–9.
16. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA.
2004;10(2):185–91.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281–97.
18. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5′UTR of ribosomal
protein mRNAs and enhances their translation. Mol Cell. 2008;30(4):460–71.
19. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, et al. miR-24 regulates apoptosis by
targeting the open reading frame (ORF) region of FAF1 in cancer cells.
PLoS One. 2010;5(2):e9429.
20. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer
diagnosis. Oncogene. 2006;25(46):6220–7.
21. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of
microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A.
2005;102(52):19075–80.
22. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al.
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 2005;65(16):7065–70.
23. Michael MZ, O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ.
Reduced accumulation of specific microRNAs in colorectal neoplasia.
Mol Cancer Res. 2003;1(12):882–91.
24. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al.
Reduced expression of the let-7 microRNAs in human lung cancers in
association with shortened postoperative survival. Cancer Res.
2004;64(11):3753–6.
25. Tsang JS, Ebert MS, van Oudenaarden A. Genome-wide dissection of
microRNA functions and cotargeting networks using gene set signatures.
Mol Cell. 2010;38(1):140–53.
26. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics,
monitoring and therapeutics. A comprehensive review. EMBO Mol Med.
2012;4(3):143–59.
27. Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, et al. The
TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase
switch that induces resistance to EGFR inhibitors. Cancer Res.
2014;74(14):3995–4005.
28. Doench JG, Sharp PA. Specificity of microRNA target selection in
translational repression. Genes Dev. 2004;18(5):504–11.
29. Martin G, Schouest K, Kovvuru P, Spillane C. Prediction and validation of
microRNA targets in animal genomes. J Biosci. 2007;32(6):1049–52.
30. Seitz H. Redefining microRNA targets. Curr Biol. 2009;19(10):870–3.
31. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al.
MicroRNA-29 family reverts aberrant methylation in lung cancer by
targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A.
2007;104(40):15805–10.
32. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin,
which is a regulator of epithelial polarity and metastasis. EMBO Rep.
2009;10(4):400–5.
33. Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, et al. MicroRNA-23b
functions as a tumor suppressor by regulating Zeb1 in bladder cancer.
PLoS One. 2013;8(7):e67686.
34. Zaman MS, Thamminana S, Shahryari V, Chiyomaru T, Deng G, Saini S, et al.
Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal
cancer. PLoS One. 2012;7(11):e50203.
35. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215–33.
36. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA
expression profiles classify human cancers. Nature. 2005;435(7043):834–8.
37. Lagana A, Russo F, Sismeiro C, Giugno R, Pulvirenti A, Ferro A. Variability in
the incidence of miRNAs and genes in fragile sites and the role of repeats
and CpG islands in the distribution of genetic material. PLoS One.
2010;5(6):e11166.
38. Lamy P, Andersen CL, Dyrskjot L, Torring N, Orntoft T, Wiuf C. Are
microRNAs located in genomic regions associated with cancer? Br J Cancer.
2006;95(10):1415–8.
39. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, et al.
An illegitimate microRNA target site within the 3′ UTR of MDM4 affects
ovarian cancer progression and chemosensitivity. Cancer Res.
2010;70(23):9641–9.
40. Mishra PJ, Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms,
new players in microRNA mediated regulation of the cell: Introducing
microRNA pharmacogenomics. Cell Cycle. 2008;7(7):853–8.
41. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7
microRNA complementary site in the KRAS 3′ untranslated region increases
non-small cell lung cancer risk. Cancer Res. 2008;68(20):8535–40.
Reddy Cancer Cell International (2015) 15:38 Page 5 of 6
6. 42. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, et al. The
human let-7a-3 locus contains an epigenetically regulated microRNA gene
with oncogenic function. Cancer Res. 2007;67(4):1419–23.
43. Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F,
et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast
cancer. J Pathol. 2008;214(1):17–24.
44. Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A, et al. Epigenetic
inactivation of microRNA-34b/c predicts poor disease-free survival in
early-stage lung adenocarcinoma. Clin Cancer Res. 2013;19(24):6842–52.
45. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al.
Specific activation of microRNA-127 with downregulation of the
proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Cancer Cell. 2006;9(6):435–43.
46. Han L, Witmer PD, Casey E, Valle D, Sukumar S. DNA methylation regulates
MicroRNA expression. Cancer Biol Ther. 2007;6(8):1284–8.
47. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M,
Blanco D, et al. A microRNA DNA methylation signature for human cancer
metastasis. Proc Natl Acad Sci U S A. 2008;105(36):13556–61.
48. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, et al.
Epigenetic regulation of microRNA expression in colorectal cancer. Int J
Cancer. 2009;125(11):2737–43.
49. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter HI, et al.
Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast
cancer cells. BMC Res Notes. 2010;3:219.
50. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M,
et al. Loss of miR-200c expression induces an aggressive, invasive, and
chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res.
2010;8(9):1207–16.
51. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of
microRNA levels by histone deacetylase inhibition. Cancer Res.
2006;66(3):1277–81.
52. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise
processing and subcellular localization. EMBO J. 2002;21(17):4663–70.
53. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, et al. Chromatin
structure analyses identify miRNA promoters. Genes Dev. 2008;22(22):3172–83.
54. Ruegger S, Grosshans H. MicroRNA turnover: when, how, and why. Trends
Biochem Sci. 2012;37(10):436–46.
55. Upton JP, Wang L, Han D, Wang ES, Huskey NE, Lim L, et al. IRE1alpha
cleaves select microRNAs during ER stress to derepress translation of
proapoptotic Caspase-2. Science. 2012;338(6108):818–22.
56. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread
microRNA repression by Myc contributes to tumorigenesis. Nat Genet.
2008;40(1):43–50.
57. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al.
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.
Nat Genet. 2006;38(9):1060–5.
58. Bui TV, Mendell JT. Myc: Maestro of MicroRNAs. Genes Cancer.
2010;1(6):568–75.
59. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH,
et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a
tumor-promoting feed-forward pathway. Genes Dev. 2010;24(24):2754–9.
60. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour
suppression. Nat Rev Cancer. 2012;12(9):613–26.
61. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6):590–610.
62. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a
induces senescence-like growth arrest through modulation of the E2F
pathway in human colon cancer cells. Proc Natl Acad Sci U S A.
2007;104(39):15472–7.
63. Hammond SM. microRNA detection comes of age. Nat Methods.
2006;3(1):12–3.
64. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, et al. An
oligonucleotide microchip for genome-wide microRNA profiling in human
and mouse tissues. Proc Natl Acad Sci U S A. 2004;101(26):9740–4.
65. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al.
Human microRNA genes are frequently located at fragile sites and genomic
regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.
66. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, et al.
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 2005;334(4):1351–8.
67. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al.
Comprehensive analysis of microRNA expression patterns in hepatocellular
carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.
68. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al.
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 2006;9(3):189–98.
69. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast
cancer signatures for invasiveness and prognosis defined by deep
sequencing of microRNA. Proc Natl Acad Sci U S A. 2012;109(8):3024–9.
70. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J.
Circulating microRNAs (miRNA) in serum of patients with prostate cancer.
Urology. 2011;77(5):1265.e9–16.
71. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al.
Changes in circulating microRNA levels associated with prostate cancer.
Br J Cancer. 2012;106(4):768–74.
72. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression
differences of circulating microRNAs in metastatic castration resistant
prostate cancer and low-risk, localized prostate cancer. Prostate.
2013;73(4):346–54.
73. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, Bernard L, et al. A serum
circulating miRNA diagnostic test to identify asymptomatic high-risk individuals
with early stage lung cancer. EMBO Mol Med. 2011;3(8):495–503.
74. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH. Plasma
microRNAs predicting clinical outcome in metastatic colorectal cancer
patients receiving first-line oxaliplatin-based treatment. Mol Oncol.
2014;8(1):59–67.
75. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum
miR-200c is a novel prognostic and metastasis-predictive biomarker in
patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.
76. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a
potential biomarker to track disease in breast cancer. PLoS One.
2012;7(10):e47003.
77. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating MiR-125b
as a marker predicting chemoresistance in breast cancer. PLoS One.
2012;7(4):e34210.
78. Farazi TA, Brown M, Morozov P, Ten Hoeve JJ, Ben-Dov IZ, Hovestadt V,
et al. Bioinformatic analysis of barcoded cDNA libraries for small RNA
profiling by next-generation sequencing. Methods. 2012;58(2):171–87.
79. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions
and therapy. Trends Mol Med. 2014;20(8):460–9.
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit
Reddy Cancer Cell International (2015) 15:38 Page 6 of 6